Journal Home > Volume 6 , Issue 1
Journal of Neurorestoratology 2018, 6(1): 11-15 https://doi.org/10.2147/JN.S148686
Expert Opinion | Open Access | Issue | Published: 26 June 2018

Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017)

Show Author's Information Qiang Ao1,*,  Juan Xiao2,3,*,  Yanqiu Yu4,  Gengsheng Mao2,  Qingyan Zou5,  Wenyong Gao2,3,  Hongyun Huang2,3( )
Department of Tissue Engineering, China Medical University, Shen Yang
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing
Department of Pathophysiology, China Medical University, Shen Yang
Guangdong 999 Brain Hospital, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Keywords:
neurorestoratology, cell culture, quality control, standardization, mesenchymal stromal cells, clinical treatment, translational medicine
Cite this article:
Ao Q, Xiao J, Yu Y, et al. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017). Journal of Neurorestoratology, 2018, 6(1): 11-15. https://doi.org/10.2147/JN.S148686
Download citation
EndNote(RIS)
BibTeX

518

Views

17

Downloads

Citations

2

Crossref

3

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Formulating common standards for the culture and quality control of umbilical cord mesenchymal stromal cells (MSCs) is crucial for the standardization of clinical neurorestorative therapy. But to date, there have been no standardized guidelines for the culture and quality control of MSCs in neurorestorative clinical application. Based on a relatively comprehensive review of published clinical studies as well as the existing methods of MSC culture and quality control, the Chinese Association of Neurorestoratology has developed standards for the culture and quality control of umbilical cord MSCs which possess the potential in neurorestorative clinical application. These guidelines include standardized training and management procedures for laboratory operators; standardized use and management of materials and equipment; standardized collection, culture and proliferation of umbilical cord MSCs; standardized management for cell preservation, transport and related safeguard measures; as well as standardization of a clean environment, routine maintenance and related tests and examinations and so on. These guidelines represent the minimum required standards for the culture and quality control of umbilical cord MSCs for potential use in current neurorestorative clinical therapy, and will be further optimized according to the progress of preclinical and clinical studies.


menu
Abstract
Full text
Outline
About this article

Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017)

Show Author's information Qiang Ao1,*, Juan Xiao2,3,*, Yanqiu Yu4, Gengsheng Mao2, Qingyan Zou5, Wenyong Gao2,3, Hongyun Huang2,3( )
Department of Tissue Engineering, China Medical University, Shen Yang
Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing
Department of Pathophysiology, China Medical University, Shen Yang
Guangdong 999 Brain Hospital, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract

Formulating common standards for the culture and quality control of umbilical cord mesenchymal stromal cells (MSCs) is crucial for the standardization of clinical neurorestorative therapy. But to date, there have been no standardized guidelines for the culture and quality control of MSCs in neurorestorative clinical application. Based on a relatively comprehensive review of published clinical studies as well as the existing methods of MSC culture and quality control, the Chinese Association of Neurorestoratology has developed standards for the culture and quality control of umbilical cord MSCs which possess the potential in neurorestorative clinical application. These guidelines include standardized training and management procedures for laboratory operators; standardized use and management of materials and equipment; standardized collection, culture and proliferation of umbilical cord MSCs; standardized management for cell preservation, transport and related safeguard measures; as well as standardization of a clean environment, routine maintenance and related tests and examinations and so on. These guidelines represent the minimum required standards for the culture and quality control of umbilical cord MSCs for potential use in current neurorestorative clinical therapy, and will be further optimized according to the progress of preclinical and clinical studies.

Keywords: neurorestoratology, cell culture, quality control, standardization, mesenchymal stromal cells, clinical treatment, translational medicine

References(28)

1.
Horwitz EM, Le Blanc K, Dominici M, et al; International Society for Cellular Therapy. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy. 2005;7(5):393-395.
DOI Google Scholar
2.
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.
DOI Google Scholar
3.
Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330-1337.
DOI Google Scholar
4.
Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151-159.
DOI Google Scholar
5.
Pansky A, Roitzheim B, Tobiasch E. Differentiation potential of adult human mesenchymal stem cells. Clin Lab. 2007;53(1-2):81-84.
Google Scholar
6.
Wachsmuth L, Söder S, Fan Z, Finger F, Aigner T. Immunolocalization of matrix proteins in different human cartilage subtypes. Histol Histopathol. 2006;21(5):477-485.
Google Scholar
7.
Chang YJ, Shih DT, Tseng CP, Hsieh TB, Lee DC, Hwang SM. Disparate mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow and umbilical cord blood. Stem Cells. 2006;24(3):679-685.
DOI Google Scholar
8.
Tondreau T, Lagneaux L, Dejeneffe M, et al. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation. 2004;72(7):319-326.
DOI Google Scholar
9.
Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105(1):93-98.
DOI Google Scholar
10.
Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98(18):10344-10349.
DOI Google Scholar
11.
Krebsbach PH, Kuznetsov SA, Bianco P, Robey PG. Bone marrow stromal cells: characterization and clinical application. Crit Rev Oral BiolMed. 1999;10(2):165-181.
DOI Google Scholar
12.
Qiao C, Xu W, Zhu W, et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int. 2008;32(1):8-15.
DOI Google Scholar
13.
Tian Guo-Zhong, Yan Jun-Hao, Huang Hong-Yun, et al. Culture, purification and identification of human bone marrow stromal cells. J Anat. 2010,33(2):317-320.
Google Scholar
14.
Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell inpatients with acute myocardial infarction. Am J Cardiol. 2004;94(1):92-95.
DOI Google Scholar
15.
Sanberg PR, Eve DJ, Willing AE, et al. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells. Cell Transplant. 2011;20(1):85-94.
DOI Google Scholar
16.
Richardson RM, Freed CR, Shimamoto SA, Starr PA. Pallidal neuronal discharge in Parkinson’s disease following intraputamenal fetal mesencephalic allograft. J Neurol Neurosurg Psychiatry. 2011;82(3):266-271.
DOI Google Scholar
17.
Liao GP, Harting MT, Hetz RA, et al. Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatr Crit Care Med. 2015;16(3):245-255.
DOI Google Scholar
18.
Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187-1194.
DOI Google Scholar
19.
Attar A, Ayten M, Ozdemir M, et al. An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy. 2011;13(1):54-60.
DOI Google Scholar
20.
Tsolaki M, Zygouris S, Tsoutsikas V, Anestakis D, Koliakos G. Treatment with adipose stem cells in a patient with moderate Alzheimer’s disease: case report. J Neurorestoratology. 2015;3:115-120.
DOI Google Scholar
21.
Freedman MS, Bar-Or A, Atkins HL, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler. 2010;16(4):503-510.
DOI Google Scholar
22.
Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008;40(4):1145-1147.
DOI Google Scholar
23.
Battistella V, de Freitas GR, da Fonseca LM, et al. Safety of autologous bone marrow mononuclear cell transplantation in patients with nonacute ischemic stroke. Regen Med. 2011;6(1):45-52.
DOI Google Scholar
24.
Friedrich MA, Martins MP, Araujo MD, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant. 2012;21(Suppl 1):S13-S21.
DOI Google Scholar
25.
Ishige I, Nagamura-Inoue T, Honda MJ, et al. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton’s jelly explants of human umbilical cord. Int J Hematol. 2009;90(2):261-269.
DOI Google Scholar
26.
Ren Y, Tian G, Wang H, et al. Quality standard for olfactory ensheathing cells of human embryonic olfactory bulb. J Clini Rehabilitative Tissue Eng Res. 2008;12(16):3156-3157.
Google Scholar
27.
Neurorestoratology Professional Committee of Chinese Medical Doctor Association. Guidelines for clinical application of neurorestoratology cell therapy of China (2015). Chin J Cell Stem Cell. 2016;6(1):1-7.
Google Scholar
28.
Jiang X, Xiao J, Ren Y, et al. Effects of storage time at 4°C on viability of olfactory ensheathing cells derived from rat olfactory bulb. Prog Anat Sci. 2011;17(5):424-427.
Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Published: 26 June 2018
Issue date: December 2018

Copyright

© The authors 2018.

Acknowledgements

We sincerely thank Professor Priscilla Song (Washington University in St Louis) for her editorial assistance in polishing this manuscript.

Rights and permissions

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Return